Serum Analysis of COVID-19 Vaccination
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 191
Special Issue Editor
Special Issue Information
Dear Colleagues,
It has been more than two years into the global pandemic of SARS-CoV-2 infection and over twelve billion doses of vaccines have been administered. Based on the extensive knowledge from other vaccination programs, there are multiple markers to evaluate vaccine efficacy. These markers include antibody levels determined by enzyme-linked immunosorbent assay (ELISA), viral and bacterial neutralization assay, interferon assay, and hemagglutination assay . ELISA is the most commonly used methodology to evaluate immunity after immunization. The ELISA based methodology generally outperforms immunochromatographic (ICT) assay for the detection of SARS-CoV-2 antibodies due to superior analytical sensitivity and specificity. For most other vaccines, a universal cut-off based on semi-quantitative or quantitative ELISA is often chosen to represent protection and immunity. As demonstrated by the Rubella vaccine, the cut-off value should be continuously monitored and adjusted with the aid of large epidemiological studies. Due to our limited knowledge regarding the serological responses prior to breakthrough infection, it is unknown if a similar cut-off level for prevention against infection could be selected for SARS-CoV-2 vaccines.
A reliable serology test to rapidly quantify neutralizing antibody levels in a high-throughput manner is essential for diagnosis, vaccine development, and antiviral development. Even in a postvaccination era, serology tests will remain critical for studying both individuals’ and the community's protective immunity to safeguard public health around the world. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation, or review to highlight the new trends in serology tests
Prof. Dr. Anna Piekarska
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- serology
- Serum analysis
- COVID-19
- vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
